1
Country: USA | Funding: $1.5B
Intellia is a leading genome editing company focused on the development of proprietary, potentially curative therapeutics utilizing a recently developed biological tool known as the CRISPR/Cas9 system. We believe that the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing diseased genes in the human body through a single treatment course. We intend to leverage our leading scientific expertise, clinical development experience and intellectual property position to unlock broad therapeutic applications of CRISPR/Cas9 genome editing and develop a potential new drug class.
Intellia is a leading genome editing company focused on the development of proprietary, potentially curative therapeutics utilizing a recently developed biological tool known as the CRISPR/Cas9 system. We believe that the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing diseased genes in the human body through a single treatment course. We intend to leverage our leading scientific expertise, clinical development experience and intellectual property position to unlock broad therapeutic applications of CRISPR/Cas9 genome editing and develop a potential new drug class.
2
Country: USA | Funding: $1.2B
Beam Therapeutics develops of genome editing technologies.
Beam Therapeutics develops of genome editing technologies.
3
Country: USA | Funding: $931.6M
Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.
Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.
4
Country: USA | Funding: $630.8M
ArsenalBio is focused on integrating technologies such as CRISPR-based genome engineering, scaled and high throughput target identification, synthetic biology, and machine learning to advance a new paradigm to discover and develop in immune cell therapies.
ArsenalBio is focused on integrating technologies such as CRISPR-based genome engineering, scaled and high throughput target identification, synthetic biology, and machine learning to advance a new paradigm to discover and develop in immune cell therapies.
5
Country: USA | Funding: $459.7M
Synthego is a provider of synthetic RNA solutions for CRISPR Genome Engineering.
Synthego is a provider of synthetic RNA solutions for CRISPR Genome Engineering.
6
Country: USA | Funding: $457M
Metagenomi is using the power of metagenomics and machine learning to discover novel genome editing systems.
Metagenomi is using the power of metagenomics and machine learning to discover novel genome editing systems.
7
Country: USA | Funding: $419.3M
Verve is focused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary.
Verve is focused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary.
8
Country: USA | Funding: $407M
The mission of CRISPR Therapeutics is to develop transformative gene-based medicines for patients with serious diseases. Our therapeutic approach is to cure diseases at the molecular level using the breakthrough gene editing technology called CRISPR-Cas9. With our multi-disciplinary team of world-renowned academics, drug developers and clinicians, we are uniquely positioned to translate CRISPR-Cas9 technology into human therapeutics.
The mission of CRISPR Therapeutics is to develop transformative gene-based medicines for patients with serious diseases. Our therapeutic approach is to cure diseases at the molecular level using the breakthrough gene editing technology called CRISPR-Cas9. With our multi-disciplinary team of world-renowned academics, drug developers and clinicians, we are uniquely positioned to translate CRISPR-Cas9 technology into human therapeutics.
9
Country: USA | Funding: $317.7M
Caribou Biosciences is a pioneer in the revolutionary field of CRISPR-Cas genome editing. Our proprietary technology puts us at the forefront of the development of new medical therapies and bio-based products which offer profound benefits to both human health and society as a whole.
Caribou Biosciences is a pioneer in the revolutionary field of CRISPR-Cas genome editing. Our proprietary technology puts us at the forefront of the development of new medical therapies and bio-based products which offer profound benefits to both human health and society as a whole.
10
Country: USA | Funding: $317.8M
Emendo Biotherapeutics develops gene editing platform to expand the list of diseases amenable to treatment with gene editing, resulting in a pipeline of hematology and ophthalmology programs.
Emendo Biotherapeutics develops gene editing platform to expand the list of diseases amenable to treatment with gene editing, resulting in a pipeline of hematology and ophthalmology programs.
11
Country: USA | Funding: $264.5M
The CRISPR-based platform for disease detection.
The CRISPR-based platform for disease detection.
12
Country: USA | Funding: $128.7M
Locus Biosciences develops CRISPR-engineered precision antibacterial platform designed to revolutionize the treatment of bacterial disease.
Locus Biosciences develops CRISPR-engineered precision antibacterial platform designed to revolutionize the treatment of bacterial disease.
13
Country: USA | Funding: $123M
Epic Bio's strength is a relentless focus on ushering in a new era of gene regulation.
Epic Bio's strength is a relentless focus on ushering in a new era of gene regulation.
14
Country: Denmark | Funding: $103.4M
SNIPR Biome is to develop CRISPR-based medicines that give hope for effective and safe treatment of difficult-to-treat diseases in the future.Precision killing of bacteria has the impact to revolutionise the management of untreatable and difficult-to-treat infections as well as complex diseases directly impacted by the human microbiota.
SNIPR Biome is to develop CRISPR-based medicines that give hope for effective and safe treatment of difficult-to-treat diseases in the future.Precision killing of bacteria has the impact to revolutionise the management of untreatable and difficult-to-treat infections as well as complex diseases directly impacted by the human microbiota.
15
Country: USA | Funding: $45M
Exonics Therapeutics is developing transformative SingleCut CRISPR gene repair therapies for devastating genetic neuromuscular diseases
Exonics Therapeutics is developing transformative SingleCut CRISPR gene repair therapies for devastating genetic neuromuscular diseases
